



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Candesartan (Standard)

| | |
|---------------------------|--|
| Cat. No.: | HY-B0205R |
| CAS No.: | 139481-59-7 |
| Molecular Formula: | C ₂₄ H ₂₀ N ₆ O ₃ |
| Molecular Weight: | 440.45 |
| Target: | Angiotensin Receptor; PPAR |
| Pathway: | GPCR/G Protein; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (227.04 mM)
 * "≥" means soluble, but saturation unknown.

| Solvent | Mass | Concentration | | |
|---------------------------|-------|---------------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.2704 mL | 11.3520 mL | 22.7041 mL |
| | 5 mM | 0.4541 mL | 2.2704 mL | 4.5408 mL |
| | 10 mM | 0.2270 mL | 1.1352 mL | 2.2704 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT₁-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI)^{[1][2][3]}.

REFERENCES

- [1]. Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003 Sep 6;362(9386):759-66.
- [2]. Nishimura Y, et al. Chronic peripheral administration of the angiotensin II AT₁ receptor antagonist candesartan blocks brain AT₁ receptors. *Brain Res*. 2000 Jul 14;871(1):29-38.
- [3]. Sonia Villapol, et al. Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA